SciELO - Scientific Electronic Library Online

 
vol.18 número2Leptina y artritis reumatoide, influencia de esta adipocina en la enfermedad índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Reumatología

versión On-line ISSN 1817-5996

Resumen

CARDENAS COLIN, Lorena  y  CASTILLO CHAVEZ, Luis Manuel. Immunotolerance in botulinum toxin type A treatment. Rev Cuba Reumatol [online]. 2016, vol.18, n.2, pp.142-149. ISSN 1817-5996.

Abstract Nowadays, botulinum toxin Type A is used for various disease treatment with hyperactivity muscular located and cosmetic using. botulinum toxin Type A is conformed to a protein nucleus of 150 kDa associated to a complex of 6 auxiliary non-toxic proteins. In the response to chronic treatment with botulinum toxin Type A a decrease of interlude time for toxin application has been described, which can be expressed as an effect decrease of botulinum toxin Type A. Immune mechanism was identified by a search, as well as main molecules involved in development of tolerance immune versus botulinum toxin Type A. Systematic research was performed in data bases as: Pubmed, Scielo, Imbiomed. Basics and clinical research articles published after 2000 were consulted. Focusing in publications with 4 or less years since their publication. The reduction of periodicity of dosage of BoNTA is induced by immune tolerance, it is principally mediated by major histocompatibility, antigen CD19 and interleukin-6. The immune tolerance induce an increases of dosage required for establish an effective treatment with botulinum toxin Type A; however, this does not mean a botulinum toxin dependence. Development of immune tolerance to treatments with BoNTA induces a low effectiveness of chronic treatment and evidence the necessity to researching new treatments that reduce the immune tolerance of botulinum toxin Type A. Meaning an effectivity reduces of a treatment to chronic diseases.

Palabras clave : Immune tolerance; botulinum toxin; Type A; CD19; MHC Class II; interleukin-6.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons